Terumo

Terumo EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Terumo (4543.T) as of Oct 28, 2026 is 184.74 B JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 206.91 B JPY — a change of -10.72% (lower).

EBITDA

184.74 BJPY

YoY

-10.72%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Terumo is 2026 184.74 B JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Terumo was 2025 206.91 B JPY. It decreases by -10.72% lower compared to the previous year.

The Terumo EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
118.68 B JPY
Jan 1, 2020
127.68 B JPY
Jan 1, 2021
117.15 B JPY
Jan 1, 2022
138.72 B JPY
Jan 1, 2023
140.87 B JPY
Jan 1, 2024
159.20 B JPY
Jan 1, 2025
206.91 B JPY
Jan 1, 2026
184.74 B JPY
The Terumo EBITDA history
YEAREBITDAYoY
184.74 BJPY-10.72%
206.91 BJPY+29.97%
159.20 BJPY+13.01%
140.87 BJPY+1.55%
138.72 BJPY+18.41%
117.15 BJPY-8.24%
127.68 BJPY+7.58%
118.68 BJPY-1.65%
120.67 BJPY+17.02%
103.12 BJPY+26.22%
81.70 BJPY+21.12%
67.46 BJPY+3.32%
65.29 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Terumo Stock analysis

What does Terumo do? Terumo Corporation is a Japanese company that was founded in 1921. The company is headquartered in Tokyo and specializes in the development, manufacturing, and marketing of medical products and devices. It has a global presence and employs approximately 28,000 people in over 160 countries. The company's history began with the establishment of a small medical device company called Sekisen Kenonsha, founded by a group of doctors. In 1942, the company merged with another company named Terumo Sougou Kenkyuusho and became Terumo Corporation. Since then, the company has continuously expanded and diversified its product range. Terumo's business model focuses on providing solutions to improve people's health worldwide through the development of innovative medical devices and products. The company operates in three main business areas: 1. Interventional Systems: This business area specializes in the development of catheters, stent systems, and other medical products for cardiac, peripheral, and vascular interventions. 2. Blood Systems: This business area offers a wide range of products for blood collection and processing, including disposable syringes for blood collection and venous and arterial access systems. 3. Biosciences: This business area focuses on the development of products for cell culture and regenerative medicine, including stem cell therapy and cell banks for research. Terumo distributes its products not only directly to hospitals and medical facilities but also collaborates closely with distributors and partners to reach a wider customer base. Additionally, the company invests significant resources in research and development to continuously expand its product range. Among the products that Terumo offers, some of the most advanced and innovative medical devices on the market can be found. One example is the state-of-the-art catheters and stent systems that enable doctors to perform minimally invasive procedures to treat serious cardiovascular diseases. Terumo also produces disposable syringes that are widely used due to their high quality and reliability. In recent years, Terumo has also invested in regenerative medicine by developing products for cell culture and therapy. This includes stem cell therapy products that can be used in the treatment of certain cancers and blood disorders. Overall, Terumo Corporation has a long history as one of the leading companies in the medical technology industry. With its innovative products and strong focus on research and development, the company will continue to play an important role in improving the health and well-being of people worldwide. Terumo is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Terumo stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Terumo is 184.74 B JPY in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Terumo changed from 206.91 B JPY to 184.74 B JPY, representing a -10.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Terumo since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Terumo historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Terumo

All Key Metrics — Terumo